Literature DB >> 22555447

Management of brainstem cavernous malformations.

Tarek Y El Ahmadieh1, Salah G Aoun, Bernard R Bendok, H Hunt Batjer.   

Abstract

OPINION STATEMENT: The risk of hemorrhage from brainstem cavernous malformations (BSCMs) ranges between 2.33 % and 4.1 % per patient-year across natural history studies and between 2.68 % and 6.8 % per patient-year across surgical series. The recurrent hemorrhage rate from BSCMs ranges between 5 % and 60 % per patient-year. Asymptomatic BSCMs tend to have a benign course, whereas symptomatic lesions often have a more aggressive course and carry an increasing risk of hemorrhage with subsequent bleeds. Hemorrhagic presentation, female gender, family history, and associating venous anomalies have been correlated with an increased risk of hemorrhage from BSCMs. MRI is the diagnostic imaging method of choice for the detection of CMs. Preoperative T1-weighted MRI can help assess the proximity of the lesion to the pial or ependymal surface of the brainstem and is thus essential to operative planning. Fluid attenuated inversion recovery (FLAIR) sequences can detect inflammatory activity and perilesional gliosis and may therefore correlate with an increased biological activity in the CM. This might help predict the aggressiveness of these lesions and their clinical activity. Due to the potential risks of surgery, conservative management with close follow-up should be the primary treatment option for patients with BSCMs. At least two clinically significant hemorrhagic episodes and an anatomical pial representation of the lesion are required before considering surgical intervention as an option because of the potential irreversible neurological damage to the patient. Life-threatening bleeds and rapidly progressive neurological deterioration are also potential indications for surgery. Complete removal of BSCMs when feasible is crucial to the prevention of future hemorrhage from BSCMs. An intraoperative ultrasound and a post-operative MRI can be used to rule out any unnoticed residual lesion. Minimizing the risk of surgery can be achieved by undergoing a case-based selection of the optimal surgical approach that allows for easy access to the lesion with minimal manipulation of normal neural tissues. Preserving any associated venous anomaly during surgery is crucial in order to avoid any undesirable hemorrhagic infarction. Advanced imaging techniques, such as diffusion tensor imaging integrated with intra-operative neuronavigation MRI, can be used to determine the anatomical relation between BSCM and the surrounding eloquent structures. Radiosurgery is not considered an effective treatment option for BSCMs. It is reserved only for extremely biologically aggressive lesions that cannot be accessed surgically.

Entities:  

Year:  2012        PMID: 22555447     DOI: 10.1007/s11936-012-0181-x

Source DB:  PubMed          Journal:  Curr Treat Options Cardiovasc Med        ISSN: 1092-8464


  112 in total

Review 1.  Modifications to the orbitozygomatic approach. Technical note.

Authors:  G Michael Lemole; Jeffrey S Henn; Joseph M Zabramski; Robert F Spetzler
Journal:  J Neurosurg       Date:  2003-11       Impact factor: 5.115

2.  De novo formation of a cavernous malformation of the brain in the presence of a developmental venous anomaly.

Authors:  S Cakirer
Journal:  Clin Radiol       Date:  2003-03       Impact factor: 2.350

3.  Supracerebellar infratentorial approach to cavernous malformations of the brainstem: surgical variants and clinical experience with 45 patients.

Authors:  Jean G de Oliveira; Gregory P Lekovic; Sam Safavi-Abbasi; Cassius V Reis; Ricardo A Hanel; Randall W Porter; Mark C Preul; Robert F Spetzler
Journal:  Neurosurgery       Date:  2010-02       Impact factor: 4.654

4.  Subtemporal transtentorial resection of cavernous malformations involving the pyramidal tract in the upper pons and mesencephalon.

Authors:  Juraj Steňo; Ivan Bízik; Jana Steňová; Gabriela Timárová
Journal:  Acta Neurochir (Wien)       Date:  2011-08-16       Impact factor: 2.216

Review 5.  Cryptic vascular malformations: controversies in terminology, diagnosis, pathophysiology, and treatment.

Authors:  W P Dillon
Journal:  AJNR Am J Neuroradiol       Date:  1997 Nov-Dec       Impact factor: 3.825

6.  A single institution series of cavernomas of the brainstem.

Authors:  Girish Menon; C V Gopalakrishnan; B R M Rao; Suresh Nair; Jayanand Sudhir; Mridul Sharma
Journal:  J Clin Neurosci       Date:  2011-07-13       Impact factor: 1.961

7.  Quality of life after brainstem cavernoma surgery in 71 patients.

Authors:  Thomas Dukatz; Johannes Sarnthein; Helmut Sitter; Oliver Bozinov; Ludwig Benes; Ulrich Sure; Helmut Bertalanffy
Journal:  Neurosurgery       Date:  2011-09       Impact factor: 4.654

8.  Formation of intracerebral cavernous malformations after radiation treatment for central nervous system neoplasia in children.

Authors:  J J Larson; W S Ball; K E Bove; K R Crone; J M Tew
Journal:  J Neurosurg       Date:  1998-01       Impact factor: 5.115

9.  Treatment and outcome of children with cerebral cavernomas: a survey on 32 patients.

Authors:  Alessandro Consales; Gianluca Piatelli; Marcello Ravegnani; Marco Pavanello; Pasquale Striano; Maria Luisa Zoli; Valeria Capra; Andrea Rossi; Maria Luisa Garrè; Maria Grazia Calevo; Armando Cama
Journal:  Neurol Sci       Date:  2009-10-16       Impact factor: 3.307

10.  Cavernous malformations of the brainstem: three-dimensional-constructive interference in steady-state magnetic resonance imaging for improvement of surgical approach and clinical results.

Authors:  Stefan Zausinger; Indra Yousry; Hartmut Brueckmann; Robert Schmid-Elsaesser; Joerg-Christian Tonn
Journal:  Neurosurgery       Date:  2006-02       Impact factor: 4.654

View more
  1 in total

1.  Pathological Evaluation of Radiation-Induced Vascular Lesions of the Brain: Distinct from De Novo Cavernous Hemangioma.

Authors:  Yoon Jin Cha; Ji Hae Nahm; Ji Eun Ko; Hyun Joo Shin; Jong-Hee Chang; Nam Hoon Cho; Se Hoon Kim
Journal:  Yonsei Med J       Date:  2015-11       Impact factor: 2.759

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.